S3 guidelines on breast cancer: locoregional treatment

被引:0
|
作者
Fehm T. [1 ]
Wöckel A. [2 ]
Kühn T. [3 ]
机构
[1] Universitätsfrauenklinik Düsseldorf, Moorenstraße 4, Düsseldorf
[2] Universitätsfrauenklinik Würzburg, Würzburg
[3] Frauenklinik Esslingen, Esslingen
来源
Der Gynäkologe | 2018年 / 51卷 / 7期
关键词
Breast neoplasms; Neoadjuvant therapy; Prophylactic mastectomy; Resection margins; Sentinel lymph node biopsy;
D O I
10.1007/s00129-018-4264-y
中图分类号
学科分类号
摘要
In the updated S3 guidelines on “Diagnosis, therapy and follow-up of breast cancer”, locoregional therapy has been significantly revised due to new clinical study data. The focus of the updated version is on de-escalation of surgery on the breast and axilla in early stage breast cancer. The new definition of adequate resection margins requires “no ink on tumor” which will minimize the rate of re-excisions. Also, prophylactic mastectomy of the contralateral breast in patients without BRCA status or familial high-risk situation is still not indicated. Axillary lymph node dissection can be safely avoided in patients with 1–2 metastatic sentinel lymph nodes who undergo breast-conserving surgery with whole-breast radiotherapy. Major revisions have been made on the recommendations regarding a sentinel lymph node biopsy (SNLB) in patients with primary systemic therapy (PST). The SNLB after PST is now defined as the standard treatment in patients with initially clinically negative lymph nodes; however, a complete axillary dissection must be performed in initially lymph node positive patients regardless of the response to PST. Overall, the new recommendations of the S3 guidelines enable in many cases a de-escalation of surgical treatment and thus a reduction of morbidity. © 2018, Springer Verlag. All rights reserved.
引用
收藏
页码:526 / 530
页数:4
相关论文
共 50 条
  • [1] S3 guidelines on breast cancer: locoregional recurrence
    Brucker S.Y.
    Hartkopf A.D.
    Janni W.
    [J]. Der Gynäkologe, 2018, 51 (7): : 556 - 559
  • [2] S3 Guidelines on Breast Cancer - Current Amendments
    Kreienberg, R.
    [J]. GYNAKOLOGE, 2012, 45 (06): : 436 - 437
  • [3] What's new in the S3 guidelines for breast cancer
    Lebeau, A.
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2007, 203 (05) : 263 - 263
  • [4] 2012 S3 guidelines on breast cancer follow-up
    Hack, C. C.
    Lux, M. P.
    Gerber, B.
    Bani, M. R.
    Schulz-Wendtland, R.
    Beckmann, M. W.
    [J]. GYNAKOLOGE, 2012, 45 (06): : 460 - 466
  • [5] Breast cancer: current recommendations for pathologists on the basis of the S3 guidelines
    Lebeau, A.
    Kreipe, H.
    Dietel, M.
    Schlake, W.
    Kreienberg, R.
    [J]. PATHOLOGE, 2013, 34 (04): : 293 - 304
  • [6] Zusammenfassung – S3‑Leitlinien PankreaskarzinomSynopsis—S3 guidelines pancreatic cancer
    Christiane J. Bruns
    [J]. Der Chirurg, 2022, 93 (5): : 427 - 428
  • [7] Current amendments to the S3 guidelines on breast cancer. Surgical therapy
    Blohmer, J. -U.
    [J]. GYNAKOLOGE, 2012, 45 (06): : 438 - 442
  • [8] Updating Guidelines: The S3 Treatment Guidelines for Alcohol and Tobacco
    Batra, Anil
    Kiefer, Falk
    [J]. SUCHT-ZEITSCHRIFT FUR WISSENSCHAFT UND PRAXIS, 2021, 67 (02): : 51 - 53
  • [9] Breast cancer: do the updated S3 guidelines bring anything new?: Current innovations of the S3 guidelines on early recognition, diagnostics, treatment and aftercare of breast cancer (AWMF register number: 032-045 OL)
    Wöckel A.
    Stüber T.
    [J]. Der Gynäkologe, 2018, 51 (10): : 807 - 815
  • [10] S3 guidelines on diagnostics and treatment of cervical cancer. Demands on pathology
    Horn, L. -C.
    Beckmann, M. W.
    Follmann, M.
    Koch, M. C.
    Mallmann, P.
    Marnitz, S.
    Schmidt, D.
    [J]. PATHOLOGE, 2015, 36 (06): : 585 - 593